A Study of T-20 in HIV-Positive Adults
- Conditions
- HIV Infections
- Registration Number
- NCT00002228
- Lead Sponsor
- Trimeris
- Brief Summary
The purpose of this study is to see if it is safe and effective to give T-20 to HIV-positive adults. T-20 is an anti-HIV drug.
- Detailed Description
Patients are randomly placed into 1 of 6 groups: 4 dose levels of T-20 are given by subcutaneous infusion and 2 by subcutaneous injection. The entire study lasts 7 weeks; including a 2-week screening period, followed by 28 days of treatment and 1 week of follow-up.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 78
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (11)
Northwestern Univ / Infect Dis Div / Pasavant Pav 828
🇺🇸Chicago, Illinois, United States
Johns Hopkins Hosp
🇺🇸Baltimore, Maryland, United States
Quest Clinical Research
🇺🇸San Francisco, California, United States
Univ North Carolina at Chapel Hill / Dept of Medicine
🇺🇸Chapel Hill, North Carolina, United States
Univ of Alabama at Birmingham / 1917 AIDS O/P Cln
🇺🇸Birmingham, Alabama, United States
IDC Research Initiative
🇺🇸Altamonte Springs, Florida, United States
San Francisco Gen Hosp
🇺🇸San Francisco, California, United States
NYU Med Ctr / C & D Building
🇺🇸New York, New York, United States
CRI of New England
🇺🇸Brookline, Massachusetts, United States
Univ of Texas / Thomas Street Clinic
🇺🇸Houston, Texas, United States
UCLA School of Medicine / Ctr for Research and Education
🇺🇸Los Angeles, California, United States